Ozempic And Wegovy
-
{
- All
- News
-
Ozempic And Wegovy Weight Loss Eventually Plateaus, Study Explains Why
While semaglutide has shown impressive results in aiding weight loss, many users may experience a plateau after an initial period of significant weight loss.
-
Popular Weight Loss Drug Wegovy Linked To Rare Blinding Eye Condition, Finds Study
The study does not say that Wegovy directly causes blindness. Instead, researchers found a strong link between the drug and a condition called ischemic optic neuropathy.
-
Your Genes May Decide How Well Weight Loss Drugs Work: Study
The research suggested that some of the same gene variants associated with better weight loss were also linked to stronger gastrointestinal side effects such as nausea or vomiting.
-
On Ozempic Or Wegovy? Doctors Say Stop Before Surgery, Here's Why
The ASA guidance suggests that patients on GLP-1 drugs should consult their healthcare providers well in advance of any planned surgery.
-
From Ozempic To Bariatric Surgery, Delhi Doctor Ranks 7 Weight-Loss Methods
Not everyone can or should opt for Ozempic, Mounjaro, or bariatric surgery for weight loss. The doctor lists seven methods and explains who they suit best
-
Can Using Ozempic Cause Your Hair To Fall Out? Experts Explain
Ozempic can lead to potential thinning of hair strands. Here is what Dr Neha Shah, Dr Sharmatha, Dr Narayanan A, Dr Gaurang Krishna, and Dr Krishna want to convey to the people using Ozempic.
-
GLP-1 Should Not Be Used As A Quick Fix For Weight Loss And Diabetes Management, Warns Top Experts
Experts warn that GLP1 drugs like Ozempic and Wegovy aren't quick fixes. There are misuse risks that are involved as shortages, side effects, and weight regain are possible without medical supervision.
-
From Diabetes To Weight Loss: How Semaglutide Became The Blockbuster Behind Ozempic, Wegovy
From a diabetes drug to a global weight-loss phenomenon, semaglutide has reshaped modern medicine. As patents expire, cheaper versions may expand access, raising questions about affordability, safety and long-term impact.
-
Tanmay Bhat Says He Had No Hunger Suppression While On Weight Loss Drugs; Here's Why
While GLP-1 medications are highly effective for many, an estimated 13% to 25% of users may be considered non-responders who do not experience desired appetite suppression or weight loss.
-
Weight-Loss Drugs Set To Get Cheaper In India As Semaglutide Patents Expire
The cost of popular weight-loss injections like Ozempic and Wegovy is expected to fall in India as patents on semaglutide expire in March 2026, paving the way for generic versions and wider access to anti-obesity medications.
-
Novo Nordisk Sues Telehealth Company Over 'Knock-Off' Weight Loss Drugs, Flags Patient Safety Risks
The lawsuit, filed in the US, alleges that Hims infringed Novo Nordisk's patent by mass marketing compounded semaglutide products that have not been cleared by the US Food and Drug Administration (FDA).
-
6 In 10 Indians Suffering From Obesity-Related Problems: New Survey Says GLP-1 Drugs To Play Role In Treatment
GLP-1 drugs mimic the GLP-1 hormone in the body, which helps to treat type 2 diabetes and obesity. In India, GLP-1 RAs are available under various names; Ozempic, Wegovy and Mounjaro.
-
Ozempic Maker's Weight Loss Pill Gets Key Clearance In US, Launch Days Away
The US FDA has approved Wegovy pill, the first oral GLP-1 drug for weight loss. With Ozempic already in India, experts say this signals a major shift in obesity care, raising hopes, questions on access, cost and regulation for Indians.
-
Popular Weight-Loss Drugs Like Wegovy Fail To Lower Obesity-Related Cancer Risks, Study Finds
Researchers analysed 48 previously-conducted trials which examined the safety and efficacy of GLP-1 drugs on people with type 2 diabetes, overweight, or obesity. These studies involved a total of more than 94,000 participants.
-
Ozempic Enters India: Diabetes Drug, Not A Miracle Fix, Novo Nordisk MD To NDTV
In an exclusive interaction with NDTV, Managing Director of Novo Nordisk India, Vikrant Shrotriya, said the launch of injectable semaglutide marks a significant moment for diabetes treatment.
-
Ozempic And Wegovy Weight Loss Eventually Plateaus, Study Explains Why
While semaglutide has shown impressive results in aiding weight loss, many users may experience a plateau after an initial period of significant weight loss.
-
Popular Weight Loss Drug Wegovy Linked To Rare Blinding Eye Condition, Finds Study
The study does not say that Wegovy directly causes blindness. Instead, researchers found a strong link between the drug and a condition called ischemic optic neuropathy.
-
Your Genes May Decide How Well Weight Loss Drugs Work: Study
The research suggested that some of the same gene variants associated with better weight loss were also linked to stronger gastrointestinal side effects such as nausea or vomiting.
-
On Ozempic Or Wegovy? Doctors Say Stop Before Surgery, Here's Why
The ASA guidance suggests that patients on GLP-1 drugs should consult their healthcare providers well in advance of any planned surgery.
-
From Ozempic To Bariatric Surgery, Delhi Doctor Ranks 7 Weight-Loss Methods
Not everyone can or should opt for Ozempic, Mounjaro, or bariatric surgery for weight loss. The doctor lists seven methods and explains who they suit best
-
Can Using Ozempic Cause Your Hair To Fall Out? Experts Explain
Ozempic can lead to potential thinning of hair strands. Here is what Dr Neha Shah, Dr Sharmatha, Dr Narayanan A, Dr Gaurang Krishna, and Dr Krishna want to convey to the people using Ozempic.
-
GLP-1 Should Not Be Used As A Quick Fix For Weight Loss And Diabetes Management, Warns Top Experts
Experts warn that GLP1 drugs like Ozempic and Wegovy aren't quick fixes. There are misuse risks that are involved as shortages, side effects, and weight regain are possible without medical supervision.
-
From Diabetes To Weight Loss: How Semaglutide Became The Blockbuster Behind Ozempic, Wegovy
From a diabetes drug to a global weight-loss phenomenon, semaglutide has reshaped modern medicine. As patents expire, cheaper versions may expand access, raising questions about affordability, safety and long-term impact.
-
Tanmay Bhat Says He Had No Hunger Suppression While On Weight Loss Drugs; Here's Why
While GLP-1 medications are highly effective for many, an estimated 13% to 25% of users may be considered non-responders who do not experience desired appetite suppression or weight loss.
-
Weight-Loss Drugs Set To Get Cheaper In India As Semaglutide Patents Expire
The cost of popular weight-loss injections like Ozempic and Wegovy is expected to fall in India as patents on semaglutide expire in March 2026, paving the way for generic versions and wider access to anti-obesity medications.
-
Novo Nordisk Sues Telehealth Company Over 'Knock-Off' Weight Loss Drugs, Flags Patient Safety Risks
The lawsuit, filed in the US, alleges that Hims infringed Novo Nordisk's patent by mass marketing compounded semaglutide products that have not been cleared by the US Food and Drug Administration (FDA).
-
6 In 10 Indians Suffering From Obesity-Related Problems: New Survey Says GLP-1 Drugs To Play Role In Treatment
GLP-1 drugs mimic the GLP-1 hormone in the body, which helps to treat type 2 diabetes and obesity. In India, GLP-1 RAs are available under various names; Ozempic, Wegovy and Mounjaro.
-
Ozempic Maker's Weight Loss Pill Gets Key Clearance In US, Launch Days Away
The US FDA has approved Wegovy pill, the first oral GLP-1 drug for weight loss. With Ozempic already in India, experts say this signals a major shift in obesity care, raising hopes, questions on access, cost and regulation for Indians.
-
Popular Weight-Loss Drugs Like Wegovy Fail To Lower Obesity-Related Cancer Risks, Study Finds
Researchers analysed 48 previously-conducted trials which examined the safety and efficacy of GLP-1 drugs on people with type 2 diabetes, overweight, or obesity. These studies involved a total of more than 94,000 participants.
-
Ozempic Enters India: Diabetes Drug, Not A Miracle Fix, Novo Nordisk MD To NDTV
In an exclusive interaction with NDTV, Managing Director of Novo Nordisk India, Vikrant Shrotriya, said the launch of injectable semaglutide marks a significant moment for diabetes treatment.
